Immune Mediators in Vitreous Fluids from Patients with Vitreoretinal B-Cell Lymphoma

Usui, Yoshihiko; Wakabayashi, Yoshihiro; Okunuki, Yoko; Kimura, Kazuhiro; Tajima, Kazuki; Matsuda, Reiko; Ueda, Shunichiro; Ma, Juan; Nagai, Takeshi; Mori, Hideki; Kezuka, Takeshi; Nagao, Toshitaka; Gotô, Hiroshi

doi:10.1167/iovs.11-8719

Cited by 22 publications

(22 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, only one study analyzing aqueous concentration of cytokines other than IL-10 and IL-6 in vitreoretinal lymphoma has been published, and that was during the revision phase of this article. 23 As opposed to our study, these authors evaluated the cytokines in the vitreous at the time of diagnosis. They had 21 Asian patients and 27 controls.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Vitreoretinal Lymphoma versus Uveitis: Cytokine Profile and Correlations

Caraballo¹,

Snyder

Johnston³

et al. 2014

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 85%

“…Only IL-10 levels appear to be important as a way to follow treatment and to help with the diagnosis of VRL. 23 Larger collaborative series with longitudinal measurement of aqueous humor interleukin concentrations and their response to treatment are necessary to verify these findings.…”

Section: Discussionmentioning

confidence: 99%

Vitreoretinal Lymphoma versus Uveitis: Cytokine Profile and Correlations

Caraballo¹,

Snyder

Johnston³

et al. 2014

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

show abstract

“…Aqueous humor samples were analyzed at 1:5 dilution. Cytokines including VEGF, MIP-1B, MCP1, IL-6, and IL-8 were measured using the BD CBA Flex Immunoassay Kit (BD) as described (87). A list of all other cytokines analyzed using this assay is given in the Supplemental Methods.…”

Section: Methodsmentioning

confidence: 99%

VEGF regulates local inhibitory complement proteins in the eye and kidney

Keir¹,

Firth²,

Aponik³

et al. 2016

Journal of Clinical Investigation

Self Cite

125

View full text Add to dashboard Cite

Outer retinal and renal glomerular functions rely on specialized vasculature maintained by VEGF that is produced by neighboring epithelial cells, the retinal pigment epithelium (RPE) and podocytes, respectively. Dysregulation of RPE- and podocyte-derived VEGF is associated with neovascularization in wet age-related macular degeneration (ARMD), choriocapillaris degeneration, and glomerular thrombotic microangiopathy (TMA). Since complement activation and genetic variants in inhibitory complement factor H (CFH) are also features of both ARMD and TMA, we hypothesized that VEGF and CFH interact. Here, we demonstrated that VEGF inhibition decreases local CFH and other complement regulators in the eye and kidney through reduced VEGFR2/PKC-α/CREB signaling. Patient podocytes and RPE cells carrying disease-associated CFH genetic variants had more alternative complement pathway deposits than controls. These deposits were increased by VEGF antagonism, a common wet ARMD treatment, suggesting that VEGF inhibition could reduce cellular complement regulatory capacity. VEGF antagonism also increased markers of endothelial cell activation, which was partially reduced by genetic complement inhibition. Together, these results suggest that VEGF protects the retinal and glomerular microvasculature, not only through VEGFR2-mediated vasculotrophism, but also through modulation of local complement proteins that could protect against complement-mediated damage. Though further study is warranted, these findings could be relevant for patients receiving VEGF antagonists.

show abstract

“…The second feature is that in B-cell PVRL there is predominance of IL-10 cytokine, 12 presumably elaborated by the lymphoma cells. It acts as a growth factor for B lymphocytes, along with other mediators, 36 and is also anti-inflammatory. This may stifle immune defenses against the tumor cells and produce the typical 'quiet' eye of PVRL.…”

Section: Clinical Features Of Pvrlmentioning

confidence: 99%